X

Trial Profile

A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Non-small cell lung cancer
Focus Biomarker; Pharmacogenomic; Therapeutic Use
Acronyms TOPICAL

Most Recent Events

06 Sep 2019 Results assessing the clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy, published in the European Journal of Cancer
09 Sep 2015 Results assessing values of veriStrat classifier presented at the 16th World Conference on Lung Cancer.
15 Oct 2012 Primary endpoint 'Overall-survival-duration' has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com